CAMBRIDGE, Mass.--(BUSINESS WIRE)--Helicos BioSciences Corporation (NASDAQ: HLCS) today announced the publication of a landmark study by Dr. Bradley Bernstein of the Massachusetts General Hospital describing the use of Helicos’ single molecule sequencing technology for the performance of genome-wide, epigenomic experiments using minute amounts of nucleic acid. The paper entitled “Chromatin Profiling by Directly Sequencing Small Quantities of Immunoprecipitated DNA” appeared in the online version of Nature Methods yesterday.
